Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
GMED

GMED - Globus Medical Inc Stock Price, Fair Value and News

50.76USD+0.39 (+0.77%)Delayed as of 26 Apr 2024, 11:11 am ET

Market Summary

GMED
USD50.76+0.39
Delayedas of 26 Apr 2024, 11:11 am
0.77%

GMED Alerts

  • 1 major insider sales recently.

GMED Stock Price

View Fullscreen

GMED RSI Chart

GMED Valuation

Market Cap

6.8B

Price/Earnings (Trailing)

54.27

Price/Sales (Trailing)

4.35

EV/EBITDA

20.5

Price/Free Cashflow

41.27

GMED Price/Sales (Trailing)

GMED Profitability

EBT Margin

10.54%

Return on Equity

3.14%

Return on Assets

2.47%

Free Cashflow Yield

2.42%

GMED Fundamentals

GMED Revenue

Revenue (TTM)

1.6B

Rev. Growth (Yr)

124.6%

Rev. Growth (Qtr)

60.71%

GMED Earnings

Earnings (TTM)

125.7M

Earnings Growth (Yr)

-78.75%

Earnings Growth (Qtr)

1.1K%

Breaking Down GMED Revenue

52 Week Range

48.7862.88
(Low)(High)

Last 7 days

-0.7%

Last 30 days

-2.4%

Last 90 days

-6.3%

Trailing 12 Months

-12.6%

How does GMED drawdown profile look like?

GMED Financial Health

Current Ratio

4.88

Debt/Equity

0.1

Debt/Cashflow

0.58

GMED Investor Care

Shares Dilution (1Y)

34.93%

Diluted EPS (TTM)

1.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.1B1.1B1.2B1.6B
2022961.3M973.9M998.4M1.0B
2021825.8M927.9M941.5M958.1M
2020793.0M747.4M767.3M789.0M
2019721.5M742.7M769.6M785.4M
2018654.6M675.6M693.1M713.0M
2017580.5M595.4M611.5M636.0M
2016552.4M556.3M555.0M564.0M
2015491.8M511.8M531.0M544.8M
2014443.7M450.2M460.8M474.4M
2013396.3M407.3M419.8M434.5M
2012347.9M363.0M373.5M386.0M
2011299.0M309.8M320.7M331.5M
2010000288.2M
Get all data in R, Python etc through our Historical Stock Data APIs
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Globus Medical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
norwalk leslie v
sold
-550,574
51.99
-10,590
-
Mar 01, 2024
huller kelly
sold
-405,730
54.0973
-7,500
svp, gc, corporate secretary
Mar 01, 2024
huller kelly
acquired
186,750
24.9
7,500
svp, gc, corporate secretary
Jan 18, 2024
davidar david d
gifted
-
-
-8,000
-
Sep 01, 2023
wolterman dan
acquired
-
-
24,025
-
Sep 01, 2023
deford john a
acquired
-
-
15,578
-
Sep 01, 2023
norwalk leslie v
acquired
-
-
28,009
-
May 15, 2023
lemaitre dan
acquired
1,104,780
25.4265
43,450
-
May 15, 2023
lemaitre dan
sold
-2,475,980
56.9845
-43,450
-
Feb 09, 2023
lemaitre dan
acquired
132,922
23.95
5,550
-

1–10 of 50

Which funds bought or sold GMED recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 24, 2024
Carmichael Hill & Associates, Inc.
sold off
-100
-15,987
-
 -%
Apr 24, 2024
AlphaCentric Advisors LLC
new
-
670,500
670,500
 0.40%
Apr 24, 2024
Spire Wealth Management
unchanged
-
-429
7,992
 -%
Apr 24, 2024
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/
unchanged
-
-
27,404,300
 0.19%
Apr 24, 2024
Assenagon Asset Management S.A.
sold off
-100
-2,976,410
-
 -%
Apr 23, 2024
RICE HALL JAMES & ASSOCIATES, LLC
added
26.55
676,813
3,148,940
 0.18%
Apr 23, 2024
REGIONS FINANCIAL CORP
reduced
-1.37
-2,361
324,146
 -%
Apr 23, 2024
WASHINGTON TRUST Co
unchanged
-
350
53,640
 -%
Apr 23, 2024
GODSEY & GIBB, INC
sold off
-100
-2,132
-
 -%
Apr 23, 2024
Hunter Perkins Capital Management, LLC
new
-
672,000
672,000
 0.14%

1–10 of 50

Are Funds Buying or Selling GMED?

Are funds buying GMED calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GMED
No. of Funds

GMED Alerts

Unveiling Globus Medical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
paul david c
15.76%
21,304,758
SC 13G/A
Feb 13, 2024
janus henderson group plc
5.7%
7,908,828
SC 13G/A
Feb 13, 2024
vanguard group inc
9.54%
11,277,722
SC 13G/A
Feb 13, 2024
kayne anderson rudnick investment management llc
0.00%
0
SC 13G/A
Jan 24, 2024
blackrock inc.
9.4%
10,841,823
SC 13G/A
Sep 11, 2023
vanguard group inc
14.46%
11,283,774
SC 13G/A
Sep 07, 2023
blackrock inc.
12.1%
9,456,012
SC 13G/A
Feb 14, 2023
paul david c
21.57%
21,389,400
SC 13G/A
Feb 14, 2023
kayne anderson rudnick investment management llc
7.99%
6,184,472
SC 13G
Feb 10, 2023
janus henderson group plc
5.6%
5,633,954
SC 13G/A

Recent SEC filings of Globus Medical Inc

View All Filings
Date Filed Form Type Document
Mar 19, 2024
4
Insider Trading
Mar 15, 2024
144
Notice of Insider Sale Intent
Mar 05, 2024
4
Insider Trading
Mar 01, 2024
144
Notice of Insider Sale Intent
Feb 21, 2024
10-K
Annual Report
Feb 20, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Globus Medical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
ABT
185.5B
40.1B
 -4.14% -1.72%
32.41
4.62
 -8.12% -17.45%
BDX
66.6B
19.5B
 -4.72% -10.85%
53.01
3.42
 4.02% -22.04%
ALGN
23.3B
3.9B
 -2.96% -12.43%
52.39
6.04
 3.42% 23.09%
BAX
20.4B
14.8B
 -3.18% -12.72%
7.69
1.38
 2.12% 209.17%
MID-CAP
HSIC
9.4B
12.3B
 -0.07% -10.32%
22.5
0.76
 -2.44% -22.68%
ATR
9.3B
3.5B
 -1.98% 21.26%
32.53
2.65
 4.97% 18.89%
BIO
8.0B
2.7B
 -19.10% -36.82%
-12.63
3.01
 -4.68% 82.43%
XRAY
6.3B
4.0B
 -6.58% -25.82%
-46.81
1.59
 1.10% 85.84%
AXNX
3.4B
366.4M
 -3.44% 15.93%
-559.2
9.26
 33.86% 89.83%
PDCO
2.3B
6.6B
 -4.62% -2.20%
11.94
0.35
 2.78% -0.87%
SMALL-CAP
AHCO
1.3B
3.2B
 -14.98% -16.46%
-1.88
0.4
 7.73% -1066.14%
ANIK
379.9M
166.7M
 0.99% -2.77%
-4.6
2.28
 6.67% -456.34%
ANGO
231.5M
324.0M
 7.22% -30.16%
-1.2
0.71
 -3.19% -337.41%
APYX
51.3M
52.3M
 13.28% -50.68%
-2.74
0.98
 17.61% 19.28%
AEMD
3.9M
3.7M
 -14.29% 284.62%
-0.32
1.05
 5.77% 8.23%

Globus Medical Inc News

Latest updates
Yahoo Finance • 23 hours ago
What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?
Yahoo Finance UK • 23 Apr 2024 • 03:40 pm
GMED vs. PEN: Which Stock Is the Better Value Option?
Yahoo Finance • 15 Apr 2024 • 07:00 am
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
Simply Wall St • 08 Apr 2024 • 07:00 am
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Yahoo Finance • 04 Apr 2024 • 07:00 am
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
Investing.com • 19 Mar 2024 • 07:00 am
Globus Medical director sells over $550k in company stock
Yahoo Finance • 13 Mar 2024 • 07:00 am
Here's Why You Should Retain Globus Medical (GMED) Stock Now
Yahoo Finance • 27 Feb 2024 • 08:00 am
Here's Why Globus Medical (GMED) is a Strong Value Stock
Simply Wall St • 2 months ago
Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Simply Wall St • 4 months ago
Has Globus Medical, Inc.'s (NYSE:GMED) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Globus Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue60.7%617384292277274254264231250230251227233216149191212196195183196
Gross Profit41.4%35124821520620418919517118817118717217315998.00142163151151141150
Operating Expenses37.6%34124814914915012912712517011814111811410912411311310910810453.00
  S&GA Expenses56.7%24515612012211810710710110796.0010798.0092.0089.0080.0094.0092.0088.0088.0086.0042.00
  R&D Expenses78.2%52.0029.0021.0021.0020.0019.0017.0017.0051.0016.0016.0015.0015.0014.0039.0015.0015.0015.0016.0014.007.00
EBITDA Margin-19.6%0.21*0.26*0.32*0.32*0.32*0.28*0.28*0.26*0.27*0.32*0.33*0.28*---------
Interest Expenses-132.6%-2.588.008.006.005.004.002.003.002.002.003.003.003.003.004.004.004.004.004.004.002.00
Income Taxes548.0%10.002.0017.0014.0012.0014.0016.0011.005.007.007.0012.009.009.00-1.107.009.008.009.008.005.00
Earnings Before Taxes886.0%25.003.0075.0063.0062.0061.0071.0049.0020.0054.0049.0057.0062.0053.00-21.9432.0054.0047.0047.0042.0024.00
EBT Margin-36.1%0.11*0.17*0.24*0.24*0.24*0.20*0.20*0.18*0.19*0.24*0.24*0.18*---------
Net Income1127.7%12.001.0058.0054.0058.0047.0046.0028.0011.0046.0042.0040.0055.0045.00-13.2723.0045.0037.0042.0035.0036.00
Net Income Margin-42.6%0.08*0.14*0.20*0.19*0.18*0.13*0.13*0.13*0.14*0.19*0.20*0.15*---------
Free Cashflow182.5%82.0029.0017.0037.0046.0021.0013.0025.0059.0059.0051.0050.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-5.0%5,0865,3562,2122,1502,0761,9771,9151,9991,9571,9111,8301,7381,6791,5421,4661,4791,5321,4521,3911,3361,301
  Current Assets-0.1%1,9151,9171,2101,070983920891917865981892814822812697642687637584618631
    Cash Equivalents67.1%467280306218150134151230193362269185239251166167196166118130140
  Inventory-6.3%848905336321299282266254237234231232229232224208196187173143131
  Net PPE-3.3%587607248245244236239228221216211216217215212213200197194184172
  Goodwill55.2%1,4359241991991971825.0017918011.0015615515726.00129129129129130124124
Liabilities-6.9%1,0881,16922723523021221621321619219117517312512911613011310399.00115
  Current Liabilities-8.5%39242915516815914514614114012313012412110010698.0011195.0084.0079.0096.00
  Long Term Debt1.9%417410-------------------
    LT Debt, Non Current1.9%417410-------------------
Shareholder's Equity-4.5%3,9984,1871,9851,9151,8461,7641,6991,7851,7411,7181,6391,5631,5061,4171,3371,3631,4021,3391,2881,2371,186
  Retained Earnings-15.6%1,1371,3481,3471,2891,2401,1901,1421,2321,1941,1791,1321,0901,0459929481,0001,0481,002964926893
  Additional Paid-In Capital0.4%2,8712,858657645631606582570554542509474457423388370357339325317300
Accumulated Depreciation9.8%426388364354343333322314306301294282276267258250244238231224217
Shares Outstanding7.9%113105100100100101101102101100100100---------
Float---4,600---4,300---5,900---3,500-3,300-3,300--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations107.3%104,67450,48435,02853,31363,97532,92036,88344,69076,25377,26259,18963,57080,18453,24823,06842,29354,30955,86622,59739,203-
  Share Based Compensation-45.3%12,44522,7558,5898,9538,5078,3147,8378,1527,8057,4517,6327,6985,9357,0207,3116,8076,4386,8986,3016,448-
Cashflow From Investing496.5%320,615-80,86152,22210,992-60,484-63,11027,126-13,894-243,797-6,885-143-125,114-119,0927,661-3,299-2,592-36,035-13,668-36,739-53,839-
Cashflow From Financing-16750.5%-237,2701,4251,0842,94013,59113,162-142,7626,047-1,02322,67824,9287,56427,21223,683-20,891-68,66711,1856,6191,7304,905-
  Buy Backs-------144,493-------30,80573,864-----

GMED Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME [Abstract]   
Net sales$ 1,568,476$ 1,022,843$ 958,102
Cost of sales548,174263,725239,223
Gross profit1,020,302759,118718,879
Operating expenses:   
Research and development124,01073,01597,346
Selling, general and administrative643,410432,117408,149
Provision for litigation, net4342,3415,921
Amortization of intangibles51,03217,73518,526
Acquisition-related costs68,2745,95916,984
Total operating expenses887,160531,167546,926
Operating income/(loss)133,142227,951171,953
Other income/(expense), net   
Interest income/(expense), net20,13014,2339,297
Foreign currency transaction gain/(loss)14,259(1,020)(1,423)
Other income (expense)(2,138)1,855580
Total other income/(expense), net32,25115,0688,454
Total165,393243,019180,407
Income tax provision42,52052,85031,216
Net income/(loss)122,873190,169149,191
Other comprehensive income/(loss), net of tax:   
Unrealized gain/(loss) on marketable securities13,231(14,040)(6,054)
Foreign currency translation gain/(loss)1,207(3,818)(4,673)
Total other comprehensive income/(loss), net of tax14,438(17,858)(10,727)
Comprehensive income/(loss)$ 137,311$ 172,311$ 138,464
Earnings per share:   
Basic$ 1.09$ 1.89$ 1.48
Diluted$ 1.07$ 1.85$ 1.44
Weighted average shares outstanding:   
Basic113,087100,469100,734
Diluted114,630102,643103,623

GMED Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 467,292$ 150,466
Short-term marketable securities50,497295,592
Accounts receivable, net of allowances of $8,934 and $4,724, respectively503,235213,247
Inventories848,135298,981
Prepaid expenses and other current assets44,58020,997
Income taxes receivable1,6354,061
Total current assets1,915,374983,344
Property and equipment, net of accumulated depreciation of $425,695 and $343,036, respectively586,932243,729
Operating lease right of use assets59,9315,988
Long-term marketable securities75,428495,852
Intangible assets, net924,60363,574
Goodwill1,434,540197,471
Other assets78,59037,323
Deferred income taxes10,68548,845
Total assets5,086,0832,076,126
Current liabilities:  
Accounts payable56,67136,101
Accrued expenses240,46092,169
Operating lease liabilities11,9672,536
Income taxes payable3,845990
Business acquisition liabilities61,03513,308
Deferred revenue18,36914,100
Total current liabilities392,347159,204
Business acquisition liabilities, net of current portion78,32354,950
Operating lease liabilities91,0373,475
Senior convertible notes417,400 
Deferred income taxes and other tax liabilities84,4211,779
Other liabilities24,59610,345
Total liabilities1,088,124229,753
Commitments and contingencies (Note 16)
Equity:  
Additional paid-in capital2,870,749630,952
Accumulated other comprehensive income/(loss)(10,192)(24,630)
Retained earnings1,137,2661,239,951
Total equity3,997,9591,846,373
Total liabilities and equity5,086,0832,076,126
Common Class A [Member]  
Equity:  
Common stock11478
Common Class B [Member]  
Equity:  
Common stock$ 22$ 22

About Globus Medical Inc

GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
 CEO
 WEBSITEglobusmedical.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES2600

Globus Medical Inc Frequently Asked Questions

What is the ticker symbol for Globus Medical Inc? What does GMED stand for in stocks?

GMED is the stock ticker symbol of Globus Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Globus Medical Inc (GMED)?

As of Thu Apr 25 2024, market cap of Globus Medical Inc is 6.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GMED stock?

You can check GMED's fair value in chart for subscribers.

What is the fair value of GMED stock?

You can check GMED's fair value in chart for subscribers. The fair value of Globus Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Globus Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GMED so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Globus Medical Inc a good stock to buy?

The fair value guage provides a quick view whether GMED is over valued or under valued. Whether Globus Medical Inc is cheap or expensive depends on the assumptions which impact Globus Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GMED.

What is Globus Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, GMED's PE ratio (Price to Earnings) is 54.27 and Price to Sales (PS) ratio is 4.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GMED PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Globus Medical Inc's stock?

In the past 10 years, Globus Medical Inc has provided 0.082 (multiply by 100 for percentage) rate of return.